BEUDAMED
    FDA Adverse Event Injury Summary report: N

    KINETRA

    MDR report key: 2387018 · Received December 22, 2011

    Report

    Report Number
    3007566237-2011-09331
    Event Type
    Injury
    Date Received
    December 22, 2011
    Report Date
    November 23, 2011
    Manufacturer
    MEDTRONIC NEUROMODULATION
    Product Code
    MHY
    Adverse Event
    Yes
    Report Source
    Manufacturer report
    Reporter Location
    PO
    Reporter Occupation
    OTHER

    Narratives

    Additional Manufacturer Narrative · 1

    UNK IMPLANTED: UNK EXPLANTED: UNK LEAD, MODEL: NEU_UNKNOWN. LEAD: LOT# UNKNOWN, SERIAL# UNK, IMPLANTED: UNK, EXPLANTED: UNK. LEAD: MODEL NEU, UNKNOWN. EXT: LOT# UNK, SERIAL# UNKNOWN, IMPLANTED: UNK, EXPLANTED: UNK. LEAD: MODEL NEU UNKNOWN. EXT: LOT# UNK, SERIAL# UNKNOWN, IMPLANTED: UNK, EXPLANTED: UNK.

    Description of Event or Problem · 1

    REAL, R., LINHARES, P., FERNANDES, H., ROSAS, M. J., GAGO, M., F., PEREIRA, J., VAZ, R. ROLE OF TC-SULESOMAB IMMUNOSCINTIGRAPHY IN THE MANAGEMENT OF INFECTION FOLLOWING DEEP BRAIN STIMULATION SURGERY. NEUROL RESEARCH INTERNATIONAL. 2011;2011:817951. DOI: 10.11 55/2011/817951. SUMMARY: THE AUTHORS EVALUATE THE POTENTIAL ROLE OF IMMUNOSCINTIGRAPHY WITH TC-LABELLED ANTIGRANULOCYTE ANTIBODY FRAGMENTS (TC-SULESOMAB) IN THE MANAGEMENT OF INFECTION IN PARKINSON'S DISEASE (PD) PATIENTS FOLLOWING DEEP BRAIN STIMULATION (DBS), THE PRESENCE OF WHICH CORRELATES WITH THE EXTENT OF INFECTION, THUS I) ALLOWING THE DIFFERENTIATION OF PATIENTS WHO SHOULD REMOVE THE ENTIRE SYSTEM VS. THOSE WHO COULD RECEIVE A MORE CONSERVATIVE TREATMENTS; AND II) HELPING TO DETERMINE THE MOST APPROPRIATE TIMING FOR RE-IMPLANTATION. THIS STUDY LOOKED AT 8 PATIENTS WITH PD WHO HAD BEEN IMPLANTED WITH BILATERAL DBS IN THE SUBTHALAMIC NUCLEUS (STN) BETWEEN (B)(6) 2002 AND (B)(6) 2008 AND HAD PERSISTENT DEVICE-RELATED SKIN EROSION AND/OR INFECTION. THE LEADS AND STIMULATOR WERE PLACED IN A SINGLE STAGE PROCEDURE. EACH PATIENT EXPERIENCED SKIN EROSION AND/OR INFECTION THAT WAS TREATED WITH ANTIBIOTICS, BUT HAD PERSISTENT OR RECURRENT WOUND DEHISCENCE. IMMUNOSCINTIGRAPHY WAS THEN PERFORMED BETWEEN (B)(6) 2009 AND (B)(6) 2010 AND EACH PATIENT WAS THEN SUBJECTED TO WOUND DEBRIDEMENT ALONE OR IN COMBINATION WITH EITHER PARTIAL OR COMPLETE HARDWARE REMOVAL. REPORTED EVENT: A MALE PATIENT WHO WAS IMPLANTED WITH DBS FOR PD AT THE AGE OF (B)(6) PRESENTED WITH WOUND DEHISCENCE OF THE RETROAURICULAR INCISION. THE PATIENT HAD AN (B)(6). THE PATIENT HAD NO PRIOR SURGERIES AND HAD BEEN TREATED WITH ANTIBIOTICS FOR A PROLONGED PERIOD OF TIME. BECAUSE OF THE PERSISTENT OR RECURRENT WOUND DEHISCENCE A TC-SULESOMAB IMMUNOSCINTIGRAPHY WAS PERFORMED. THE TC-SULESOMAB IMMUNOSCINTIGRAPHY SHOWED FOCAL UPTAKE (RETROAURICULAR). A SURGERY WAS PERFORMED DURING WHICH SERIOUS EXUDATE WAS FOUND UNDER THE RETROAURICULAR WOUND. THE PATIENT WAS SUBJECTED TO WOUND DEBRIDEMENT. THE INFECTION DID NOT HEAL AND THE PATIENT SUBSEQUENTLY UNDERWENT REMOVAL OF THE IPG AND EXTENSION CABLES. THE INFECTION THEN HEALED AND THE PATIENT HAD A NORMAL SCAN. THE PATIENT WAS RE-IMPLANTED WITH A NEW SYSTEM 8 MONTHS LATER. SEE LITERATURE ARTICLE ATTACHED IN MFR REPORT# 3007566237-2011-09329.

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    1 KINETRA STIMULATOR, ELECTRICAL, IMPLANTED, FOR PARKINSONIAN TREMOR MHY MEDTRONIC NEUROMODULATION 7428

    Patients

    Seq Age Sex Outcome Treatment
    1 Required Intervention LEAD MODEL NEU_UNKNOWN_LEAD LOT# UNKNOWN SERIAL#